The clinical and cost-effectiveness of sunitinib for the treatment of gastrointestinal stromal tumours: a critique of the submission from Pfizer

Mary Bond; Martin Hoyle; Tiffany Moxham; Mark Napier; Rob Anderson

The clinical and cost-effectiveness of sunitinib for the treatment of gastrointestinal stromal tumours: a critique of the submission from Pfizer

Mary Bond , Martin Hoyle, Tiffany Moxham, Mark Napier, Rob Anderson

Research output: Book/Report › Commissioned report

Original language	English
Publisher	University of Exeter
Commissioning body	National Institute for Health and Care Excellence (NICE)
Number of pages	101
Publication status	Published - 2009
Externally published	Yes

Access to Document

https://www.journalslibrary.nihr.ac.uk/programmes/hta/088901/#/

Cite this

@book{addbe496445c48f49ac8dafeb43124a6,

title = "The clinical and cost-effectiveness of sunitinib for the treatment of gastrointestinal stromal tumours: a critique of the submission from Pfizer",

author = "Mary Bond and Martin Hoyle and Tiffany Moxham and Mark Napier and Rob Anderson",

year = "2009",

language = "English",

publisher = "University of Exeter",

}

TY - BOOK

T1 - The clinical and cost-effectiveness of sunitinib for the treatment of gastrointestinal stromal tumours

T2 - a critique of the submission from Pfizer

AU - Bond , Mary

AU - Hoyle, Martin

AU - Moxham, Tiffany

AU - Napier, Mark

AU - Anderson, Rob

PY - 2009

Y1 - 2009

UR - https://www.nice.org.uk/guidance/ta179

UR - https://www.scopus.com/pages/publications/84886943002

M3 - Commissioned report

BT - The clinical and cost-effectiveness of sunitinib for the treatment of gastrointestinal stromal tumours

PB - University of Exeter

ER -

The clinical and cost-effectiveness of sunitinib for the treatment of gastrointestinal stromal tumours: a critique of the submission from Pfizer

Access to Document

Other files and links

Cite this